Clinical trials: Autoimmunity, Inflammation
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Safety of Splenic Stimulation for RA
This study will evaluate the safety and tolerability of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories.
- Trial name
- NCT04955899
- Testing
- Active Stimulation
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Galvani Bioelectronics
Rheumatoid Arthritis
Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis
The primary objective of this study is to assess the reduction of systemic inflammation as measured by serum levels of C-reactive protein (CRP).
- Trial name
- ACCORD-RA (NCT00545454)
- Testing
- SSR150106
- Where
- 7 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 79 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
The SPECTRA Study
The purpose of this study is to compare IL-1ra and the combination of IL-1ra and PEGsTNF-RI with respect to their ability to reduce inflammation and bone and cartilage destruction in the synovium of subjects with rheumatoid…
- Trial name
- NCT00537667
- Testing
- anakinra, anakinra and PEG sTNF-R1
- Volunteers
- 22 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Osteoarthritis
A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis
This study is being conducted to validate various biomarkers in patients with RA with varying levels of disease severity. Subjects with a diagnosis of rheumatoid arthritis (RA) will be included as controls.
- Trial name
- NCT00242853
- Testing
- Power doppler ultrasonography, High frequency ultrasonography, Exhaled nitric oxide assessment
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study.
- Trial name
- FUSION (NCT05798520)
- Testing
- BIIB091, DRF
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 127 people
- Sponsor
- Biogen
Rheumatoid Arthritis
The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis
Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.
- Trial name
- NCT03511625
- Testing
- Acthar Injectable Product, Depo medrol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Attune Health Research, Inc.
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Inflammation, Rheumatoid Arthritis
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0000 in subjects with…
- Trial name
- NCT01223911
- Testing
- NNC 0151-0000-0000
- Where
- 16 sites in Czechia, Denmark and 4 more
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Inflammation, Systemic Lupus Erythematosus
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and signs of bioactivity of increasing repeated doses of NNC 151-0000-0000…
- Trial name
- NCT01018238
- Testing
- NNC 0151-0000-0000
- Where
- United States
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis, Psoriatic Arthritis
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases
Rheumatic diseases regroup a variety of disorders affecting the locomotor system including joints, muscles, connective tissues and soft tissues around the joints and bones.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Trial name
- NCT03454932
- Testing
- Blood sampling
- Volunteers
- 30 people
- Sponsor
- Bone Therapeutics S.A
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
This study will evaluate the evolution of leptomeningeal lesions via leptomeningeal contrast enhancement (LMCE) presence/disappearance after treatment administration in patients with active progressive multiple sclerosis (MS).
- Trial name
- LEGATO (NCT05208840)
- Testing
- Ocrelizumab
- Where
- 2 sites in Russia
- Sponsor
- Hoffmann-La Roche